DDDavid M. DiBardino

David M. DiBardino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David M. DiBardino has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A 67-Year-Old Woman With a “Shrunken” Left Lung and Recurrent Pneumonia

    by David M. DiBardino, Kyle Bramley, Andrew Haas


  • Interventional Pulmonology

    by David M. DiBardino, Andrew R. Haas, Richard C. Month


  • Molecular testing on endobronchial ultrasound (EBUS) fine needle aspirates (FNA): Impact of triage

    by Simon Sung, John P. Crapanzano, David DiBardino, David Swinarski, William A. Bulman, Anjali Saqi

    Background: Endobronchial ultrasound (EBUS)‐guided fine needle aspiration (FNA) is performed to diagnose and stage lung cancer. Multiple studies have described the value of Rapid On‐Site Evaluation (ROSE), but often the emphasis is upon diagnosis than adequacy for molecular testing (MT). The aim was to identify variable(s), especially cytology‐related, that can improve MT.Methods: A search for EBUS‐FNAs with ROSE was conducted for lung adenocarcinomas or when this diagnosis could not be excluded. All such cases underwent reflex MT on cell blocks. The impact of cytology‐related variables [i.e., number of pass(es), dedicated pass(es) directly into media, cytotechnologist (CT), laboratory technician (LT) and triage with 1 or >1 cytologist] was evaluated. The latter category was divided into Group A [ROSE, triage and slide preparation by cytopathologist (CP) and CT at start of the procedure] and Group B (ROSE only by CT or by CT/CP after start of procedure; triage and slide preparation by CT or clinical staff). The impact of all these variables on MT was assessed.Results: A total of 100 cases were identified, and 79 had sufficient tissue for MT. Of all variables evaluated, MT was positively affected by performing a direct dedicated pass (P = 0.013) and ROSE by Group A (P = 0.033).Conclusions: ROSE with appropriate triage, including performing a dedicated pass and proper slide preparation, improves MT, and this is enhanced by having >1 cytologist at the start of the procedure. In the era of personalized medicine, “adequate” should denote sufficient tissue for diagnosis and MT.


  • Blue Bronchoscopy: Confirmation of Aberrant Pulmonary Lymphatic Perfusion During Lymphangiography

    by David M. DiBardino, Anthony R. Lanfranco, Andrew R. Haas, Maxim Itkin

    To the Editor: Thoracic lymphatic disorders comprise a wide spectrum of both benign and malignant diseases and have been referred using a variety of nomenclature.1,2 Clinically, these disorders often present as plastic bronchitis and chyloptysis. This phenomenon is more commonly encountered in pediatric age group in the setting of congenital heart disease.3 However, thoracic lymphatic anomalies causing plastic bronchitis do rarely occur in the adult population and represent a difficult patient population to treat.4 In this report, we describe a case of chyloptysis in an otherwise healthy adult where bronchoscopy was employed to confirm aberrant pulmonary lymphatic flow. A 48-year-old man with a past medical history of idiopathic recurrent chyloptysis, chylopericardium, and chylothorax was referred with progressive dyspnea. Initial symptoms of dyspnea and chyloptysis started 11 years prior. He reported intermittent wheezing, cough and hypoxemia. His oxygen saturation ranges from 87% to 91% requiring the use of long-term home oxygen therapy with activity and at night. Initially, he was treated conservatively with inhalers, steroids and antibiotics with little benefit. Over the 11 years since diagnosis, thoracentesis, attempted lymphangiogram, pleurectomy with talc pleurodesis, low triglyceride diet, and several bronchoscopies failed to improve his symptoms. Since his most recent bronchoscopy roughly 1 month ago, he reports a cough productive of thick white secretions, shortness of breath, and an increase in oxygen requirement. An intranodal lymphangiogram was performed through the inguinal lymph nodes which allowed localization of the cisterna chyli. The latter was then accessed through an anterior transabdominal approach using a Chiba needle (Cook Medical Inc., Bloomington, IN). A guide wire was used to advance into the thoracic duct. The thoracic duct was cannulated with a microcatheter.3 Contrast injection demonstrated occlusion of the superior aspect of the thoracic duct. Continued fluoroscopy revealed aberrant lymphatic flow to the right pulmonary and peribronchial lymphatics from the thoracic duct. Isosulfan blue injection into the thoracic duct with simultaneous bronchoscopy revealed abnormal bronchial submucosal lymphatic perfusion in the right bronchial tree (Fig. 1). The thoracic duct was embolized with a vascular plug and n-Butyl Cyanoacrylate glue. Repeat bronchoscopy on postoperative day 5 revealed no chyle or residual dye. Chyloptysis and plastic bronchitis rarely presents in the adult population.4 The differential diagnosis includes all disease states that cause abnormal communications between the central lymphatic system and pulmonary lymphatics with retrograde (cephalad) flow. In addition, chyloptysis could present in a patient with a chylous pleural effusion and bronchopleural fistula.4 Imaging and a complete history can be used to rule out the majority of causes due to malignant or radiation related lymphatic obstruction. Disorders associated with lymphangiomatosis, such as lymphangioleiomyomatosis, and lymphatic hypoplasia, such as yellow nail syndrome, also need consideration. After these conditions have been ruled out, primary abnormalities of the lymphatic system need to be assessed. The nonmalignant lymphatic diseases in adults affecting the lung may be primary pulmonary lymphatic anomalies or may represent pulmonary involvement of a generalized lymphatic anomaly.2 In this case, lymphangiography demonstrated a true lymphangiectasia from the thoracic duct to the right pulmonary lymphatics. Bronchoscopy during isosulfan blue injection confirmed cephalad flow toward the pulmonary and peribronchial lymphatics from the thoracic duct. When lymphangiectasis with aberrent lymphatic flow can be detected, interruption of the caudal lymphatic flow is an effective treatment option.3


  • Reply: A Cautionary Tale and Opportunities for Improvement in Transbronchial Cryobiopsy.

    by David M DiBardino, Anthony R Lanfranco, Andrew R Haas, Leslie A Litzky, Daniel Sterman, Jamie L Bessich


  • Reply: Careful Planning Reduces Cryobiopsy Complications.

    by David M DiBardino, Andrew R Haas, Anthony R Lanfranco, Leslie A Litzky, Daniel Sterman, Jamie L Bessich

  • High Complication Rate after Introduction of Transbronchial Cryobiopsy into Clinical Practice at an Academic Medical Center

    by David M. DiBardino, Andrew R. Haas, Anthony R. Lanfranco, Leslie A. Litzky, Daniel Sterman, Jamie L. Bessich

    Rationale: Transbronchial cryobiopsy is an emerging technique for obtaining biopsies of lung parenchyma. Despite limited evidence of its safety and efficacy in direct comparison with other available biopsy procedures, pulmonologists are integrating this technique into clinical practice with the hope of avoiding the risks of surgical lung biopsy. Objectives: To report the rate of severe complications and diagnostic outcomes immediately after introduction of transbronchial cryobiopsy into the clinical practice of a single-center, high-volume, interventional pulmonary group at a large academic medical center in the United States. Methods: We conducted a retrospective review of a case series. Results: Twenty-five consecutive patients underwent transbronchial cryobiopsy for a variety of indications over a period of 14 weeks. In the absence of a strict protocol, a variety of techniques were employed by four attending interventional pulmonologists and one advanced interventional pulmonology fellow to plan and complete the procedures. Three patients (12%) experienced serious hemorrhage immediately after biopsy, including one patient who survived a life-threatening bleed. Two procedures were complicated by an iatrogenic pneumothorax. One patient experienced hypercapnic respiratory failure shortly after the procedure. A definitive diagnosis was made with 14 cryobiopsies (56%). Another five biopsies (20%) contributed to a presumptive diagnosis achieved by multidisciplinary consensus. Conclusions: Transbronchial cryobiopsy may have diagnostic and safety limitations that are not yet well appreciated, given the state of the published medical literature. Major questions remain regarding the safest procedural protocol to be used when performing transbronchial cryobiopsy. Thorough planning and a high degree of caution are encouraged on first introduction of this technique into a clinical practice.


  • Open Access

    Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology

    by David M. DiBardino, David W. Rawson, Anjali Saqi, Jonas J. Heymann, Carlos A. Pagan, William A. Bulman

    Background: Next-generation sequencing (NGS) with a multi-gene panel is now available for patients with lung adenocarcinoma, but the performance characteristics and clinical utility of this testing are not well-described. We present the results of an extended 467 gene panel in a series of advanced, highly selected nonsmall cell lung cancer (NSCLC) patients using a range of specimens, including predominantly small biopsy and cytology specimens. Materials and Methods: A retrospective review of 22 NSCLC biopsies sent for NGS using an extended gene panel from January 2014 to July 2015. The customized NGS panel sequences 467 cancer-associated genes with exonic and intronic sequences obtained from purified tumor DNA. Genomic alterations, patient characteristics, and success of testing were determined. Results: The majority of samples tested were metastatic lung adenocarcinoma on final pathology. Of the 22 specimens tested, 5 (22.7%) were surgical resections and 17 (77.3%) were small biopsy and cytology specimens. Twenty-one (95%) of the specimens were adequate for full sequencing and yielded a total of 204 genomic alterations (average 8.9 per tumor), of which 17 (average 0.81 per tumor) were actionable and/or clinically relevant. Genomic alterations were found most commonly in the TP53, EGFR, EPHB1, MLL3, APC, SETD2, KRAS, DNMT3A, RB1, CDKN2A, ARID1A, EP300, KDM6B, RAD50, STK11, and BRCA2 genes. Conclusions: NGS using a comprehensive gene panel was performed successfully in 95% of all NSCLC cases in this series, including 94% small biopsy and cytology specimens and 100% surgical resections. This custom assay was performed on a range of tumor specimens and demonstrates that small specimens are able to provide a similar depth of information as larger ones. As many patients present at an advanced stage and only small specimens are obtained, the information these provide has the potential for guiding treatment in highly selected patients with advanced lung adenocarcinoma.